BIND Therapeutics (BIND) Tops Q1 EPS by 7c

BIND Therapeutics (NASDAQ: BIND) reported Q1 EPS of ($0.44), $0.07 better than the analyst estimate of ($0.51). Revenue for the quarter came in at $4.4 million versus the consensus estimate of $2.67 million.

For earnings history and earnings-related data on BIND Therapeutics (BIND) click here.

You May Also Be Interested In

• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
• Telesat Corporation (TSAT) Misses Q2 EPS by 1006c
• Zenas BioPharma, Inc. (ZBIO) Reports Q2 Loss of $1.77